Le Prostate Health Index (PHI) a-t-il une place dans l’arsenal du dépistage biologique du cancer de la prostate ? Étude préliminaire
| Autor: | J.-L. Bonnal, G. Forzy, T. Guéry |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Gynecology
medicine.medical_specialty business.industry Biochemistry (medical) Clinical Biochemistry Free psa Urology urologic and male genital diseases Clinical biomarker Clinical study Prostate-specific antigen medicine.anatomical_structure Prostate medicine Biomarker (medicine) Statistical analysis business Total psa |
| Zdroj: | Immuno-analyse & Biologie Spécialisée. 26:143-146 |
| ISSN: | 0923-2532 |
| DOI: | 10.1016/j.immbio.2011.02.003 |
| Popis: | Summary Objectives The Prostate Health Index (PHI) is calculated from concentrations of 3 different proteins: the total Prostate Specific Antigen (PSA), the free PSA and [–2]proPSA (p2PSA).We compared the PHI with 3 different markers: The total PSA, the free PSA and the free PSA/total PSA rate. Patients and methods When the total PSA was measured between 2 and 10 ng/mL, both the p2PSA and the free PSA immunoassays were performed. Statistical analysis searched a correlation between new (the p2PSA and the PHI) and usual (the total PSA, the free PSA and the free PSA/total PSA rate) markers. Results The p2PSA is correlated with the total PSA, the free PSA and the free PSA/total PSA rate but we observed a great dispersion. The PHI is not correlated with the total PSA neither with the free PSA nor with the free PSA/total PSA rate. Conclusion These results show that the PHI is an independent biomarker. A clinical study will show if the PHI is an interesting clinical biomarker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect